Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07810335

Evaluation of FlowMod System While Intermittently Partially Occluding Vena Cava Blood Flow in Subjects With ADHF

FLOW-HF will assess the impact of intermittent partial occlusion of the SVC and/or IVC, the cardiac filling pressure and the difference of effects between the two occlusion locations (SVC and IVC) using the FlowMod flow modulating device on select parameters in subjects experiencing ADHF (Acute Decompensated Heart Failure)

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tbilisi Heart And Vascular Clinic, Tbilisi, Georgia

Loading trial locations.

About this study

Intermittent occlusion of the superior vena cava (SVC) and/or inferior vena cava (IVC) might be associated with positive beneficial effects on cardiac filling pressures and improved patient outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male or females between 18 and 85 years of age

NYHA Class III-IV heart failure

Stage C-D systolic heart failure

Clinically indicated for right heart catheterization

Volume overload status of the subject confirmed by the presence of at least 1 or more of the following congestion signs or symptoms assessed by physical examination or x-ray: Peripheral edema, rales, jugular venous distension, abdominal distension or evidence of congestion by chest x-ray

Subjects with RAP >10 mmHg

Subjects with PCWP >18 mmHg

Subjects with inadequate diuresis defined as total urinary output over the most recent 8 hours prior to enrollment of <1200 mL while on a stable dose of diuretics

Subjects with eGFR >30mL/min/1.732

Exclusion criteria

Severe valvular stenosis

Severe aortic valve regurgitation

Subjects with a contraindication to contrast dye

Active myocardial ischemia (MI) or acute coronary syndrome (ACS)

ACS or MI within 30 days prior to enrollment

Contraindication to unfractionated heparin

Unable to provide informed consent

Subjects with impaired decision-making capacity

Subjects receiving mechanical circulatory support

Subjects with history of cardiac transplant

Pregnant subjects

Right atrial/ventricular thrombus

Subjects with inadequate jugular vein access due to prior jugular vein thrombosis or indwelling chronic ports or catheters or presence of vena cava filter

Inability to tolerate right heart catheterization

Subjects who have a history of major or minor stroke or TIA ≤ 12 months or subjects with a history of stroke > 12 months who have a residual neurological deficit

Hypersensitivity or contraindication to latex

Sustained ventricular tachycardia (>10 beats) within 24 hours and/or ventricular fibrillation within 24 hours

Subjects with history of CABG ≤ 3 months

Subjects with pacemaker or defibrillator leads placed through the SVC ≤ 3 months prior to procedure

Rapid atrial fibrillation (HR>120 bpm)

Systolic blood pressure < 90 mm Hg

Inability to interrupt the anticoagulation treatment

Subjects with known coagulopathy or any blood disorders

Subjects with life expectancy of <30 days or known risk for mortality within 90 days

Prior carotid interventions (stenting or endarterectomy)

Severe carotid disease

History of DVT (<6m or requiring ongoing anticoagulants for either DVT or hypercoagulable state)

History of pulmonary embolism

SVC/IVC stenosis

SVC/IVC diameter not suitable for balloon inflations

Subjects receiving hemodialysis or planning to within 30 days

Planned LVAD device placement

Subject on >2 inotropes or escalating inotropes during pre-enrollment hospitalization

Right ventricular failure based on an RA:PCWP ratio of >0.8, PAPi<1.0; or TAPSE<10

Subjects with Ejection Fraction (EF) of <15%

Treatment and study plan

FlowMod System in subjects with acute decompensated heart failure (ADHF)

Device

The FlowMod System is used in subjects with acute decompensated heart failure (ADHF) for limiting blood flow in the inferior and superior vena cava vessels to the right heart to reduce preloading of the heart.

Primary outcomes

  1. Freedom from device- or procedure-related major adverse events (MAEs) through 30 days post procedure

    Time frame: Through 30 days post procedure

    Freedom from device- or procedure-related major adverse events (MAEs) through 30 days post procedure defined as: death, myocardial infarction, major thromboembolic event, vascular damage requiring surgical intervention, hemorrhagic stroke, or prolongation of heart failure-related hospitalization, attributable to the FlowMod device or procedure

Secondary outcomes

  1. Freedom from primary endpoint MAEs

    Time frame: Through 90 days post procedure

    Defined as: death, myocardial infarction, major thromboembolic event, vascular damage requiring surgical intervention, hemorrhagic stroke, or prolongation of heart failure-related hospitalization, attributable to the FlowMod device or procedure

  2. Acute Technical Success

    Time frame: Immediately after the procedure

    Defined as successful device deployment, ability to intermittently partially occlude the SVC/IVC and successful device removal

  3. Time from device removal to hospital discharge

    Time frame: Through index discharge, an average of 24 hours

    Time from device removal to hospital discharge will be defined as the elapsed time, in hours, between the documented date and time of complete FlowMod device removal and the documented date and time of discharge from the index hospitalization.

  4. Heart failure-related re-hospitalization rates at 30 and 90 days

    Time frame: 30 days and 90 days

    defined as any hospital admission occurring after index discharge that is primarily due to worsening signs and/or symptoms of heart failure requiring inpatient treatment.

  5. Re-hospitalization rates (any cause) at 30 and 90 days

    Time frame: 30 days and 90 days

    Rate of hospital admissions occurring after index discharge for any cause

  6. Urinary spot sodium (3 hours after start of therapy)

    Time frame: 3 hours after start of therapy

    Urinary sodium concentration measured in a spot urine sample

  7. Weight loss

    Time frame: From baseline through study completion, an average of 90 days

    Change in subject body weight from baseline to protocol-specified post-treatment timepoints

  8. Time to discharge readiness

    Time frame: From post-procedure to index discharge, an average of 24 hours

    Time until the subject is considered clinically ready for safe discharge according to institutional criteria and treating physician assessment.

  9. Index admission hemodialysis or continued renal replacement therapy

    Time frame: Periprocedural hemodialysis, an average of 24 hours

    Occurrence of hemodialysis or continued renal replacement therapy during the index hospitalization following FlowMod therapy.

  10. Hemodialysis post discharge through 90 days post discharge

    Time frame: Through 90 days after index discharge

    Occurrence of hemodialysis after index hospital discharge

  11. Modified Borg Dyspnea change from baseline, at 12 hours during therapy and post device removal

    Time frame: Baseline to 12 hours during therapy and post device removal

    Change in patient-reported dyspnea severity from baseline, measured using the Modified Borg Dyspnea scale at 12 hours during therapy and after device removal

  12. Diuretic efficiency changes from baseline, at 12 hours during therapy and post device removal

    Time frame: At 12 hours and post device removal, an average of 24 hours

    Diuretic efficiency assessed by urinary output measured in milliliters (mL)

  13. EQ5D change from baseline at discharge, 30 and 90 days

    Time frame: EQ5D from Baseline at discharge, (an average of 24 hours) and at 30 days and 90 days

    Change from baseline in EQ-5D score, a standardized measure of health-related quality of life across mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with self-rated overall health status, assessed at hospital discharge, 30 days, and 90 days.

  14. eGFR change from baseline and at 24 hours after initiation of therapy or hospital discharge, whichever comes first

    Time frame: Baseline to 24 hours after initiation of therapy or hospital discharge, whichever occurs first

    Change from baseline in estimated glomerular filtration rate (eGFR), calculated based on serum creatinine and used to evaluate renal function, assessed at 24 hours after initiation of FlowMod therapy or at hospital discharge, whichever occurs first.

  15. Cystatin C changes from baseline and at 24 hours after initiation of therapy or hospital discharge, whichever comes first

    Time frame: Baseline to 24 hours after initiation of therapy or hospital discharge, whichever occurs first

    Change from baseline in Cystatin C, a blood biomarker used to assess kidney function and evaluate changes over time, assessed at 24 hours after initiation of FlowMod therapy or at hospital discharge, whichever occurs first

  16. Right atrial, pulmonary artery, PCWP and cardiac output changes from baseline, at 8 hours during therapy and end of therapy

    Time frame: Baseline, 8 hours during therapy, and end of therapy

    Change from baseline in invasive hemodynamic parameters, including right atrial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, and cardiac output, assessed at 8 hours during FlowMod therapy and at end of therapy.

Study contacts

Contact information is provided by the study sponsor or research team.

Jean-Maurice Dussartre, MD

CONTACT

[email protected]

+33672926156

Sponsors and collaborators

Lead sponsor

FlowMod, Inc.

Industry

Registry information

Official study title

An Evaluation of the FLOWMod System to Occlude Vena Cava Blood Flow in Subjects With Acute Decompensated Heart Failure

Acronym: FLOW-HF

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 9, 2026
Registry last updated
Sep 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.